Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00834067 · ClinicalTrials.gov registry record · Phase 1
Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions
A Phase 1 study, sponsored by Teva Pharmaceuticals USA.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT00834067: Completed Phase 1 study, sponsored by Teva Pharmaceuticals USA.
NCT00834067 is a Phase 1 study that has completed, run by Teva Pharmaceuticals USA. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00834067, a Phase 1 study, has completed, sponsored by Teva Pharmaceuticals USA.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The objective of this study is to compare the relative bioavailability of moexipril HCl/ hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult, non-smoking subjects under non-fasting conditions.
Interventions
- DRUG Moexipril HCl/hydrochlorothiazide 15/25 mg tablets
- DRUG UNIRETIC® 15/25 mg tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-10 |
| Est. Completion | 2003-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00834067
The ClinicalTrials.gov registry entry for NCT00834067 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Pharmaceuticals USA, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Moexipril HCl/hydrochlorothiazide 15/25 mg tablets is the first listed.
NCT00834067 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00834067 about?
NCT00834067 is a clinical study titled "Moexipril HCl/Hydrochlorothiazide 15/25 mg Tablets Under Non-Fasting Conditions". The objective of this study is to compare the relative bioavailability of moexipril HCl/ hydrochlorothiazide 15/25 mg tablets (manufactured and distributed by TEVA Pharmaceuticals USA) with that of UNIRETIC® 15/25 mg tablets (Schwartz Pharma) in healthy, adult, non-smoking subjects under non-fasting...
What is the current status of trial NCT00834067?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2003-10. Estimated completion is 2003-11.
What interventions are being tested in trial NCT00834067?
The interventions under investigation include: Moexipril HCl/hydrochlorothiazide 15/25 mg tablets (DRUG), UNIRETIC® 15/25 mg tablets (DRUG).
Who is sponsoring clinical trial NCT00834067?
This trial is sponsored by Teva Pharmaceuticals USA, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.